nivolumab
bms
['opdivo', 'check,mate,76k', 'bristol', 'bmsnews', 'bms']
 announced its blockbuster checkpoint inhibitor opdivo hit the primary endpoint in the phase iii checkmate -76k trial.
#bms #bristolmyerssquibb #pharma #biospace 
Your source for biopharma news and jobs